logo-loader
viewBetterLife Pharma Inc

BetterLife Pharma says special meeting of Altum shareholders has “overwhelming” voted to approve the planned merger

At the meeting on July 29, 2020, the group noted that 91.3% of Altum shareholders voted in favour of the merger with the emerging biotechnology company

Merger jigsaw
BetterLife is now awaiting ratification of the merger by the Canadian Securities Exchange

BetterLife Pharma Inc. (CSE:BETR) (OTCQB:BETRF) (FRA:NPAT) revealed that a special meeting of the shareholders of Altum Pharmaceuticals Inc. has “overwhelming” voted to approve the planned merger with BetterLife.

At the meeting on July 29, 2020, the group noted that 91.3% of Altum shareholders voted in favour of the merger with the emerging biotechnology company which has proprietary interferon-based therapeutic technologies. BetterLife is now awaiting ratification of the merger by the Canadian Securities Exchange.

READ: BetterLife Pharma encouraged by results of UK biotech's trial of interferon inhalation treatment for coronavirus

In a statement, Robert Metcalfe, lead director of BetterLife, said, “We are very pleased with the results of the votes from the Altum shareholders and to receive more than 91% support in favor of the merger with BetterLife.

“We look forward to the completion of the merger and advancing the development of Altum’s therapeutic treatments.”

Altum’s therapeutic pipeline consists of 3 products, including AP-003, a patent-pending interferon a2b (IFNa2b) inhalation formulation. Recent studies in China and the UK have provided data that suggest the therapeutic efficacy of interferon-based treatments for coronavirus (COVID-19).

BetterLife stressed again that it is not making any express or implied claims that Altum's AP-003 or any other product has the ability to eliminate, cure or contain the COVID-19 (or SARS-2 Coronavirus) at this time. Furthemorer, the safety and efficacy of Altum's AP-003 are under investigation and market authorization has not yet been obtained.

The company also that it has finalized an outstanding finder fee claim from Green Stream Botanicals Corp. from September 2019.

BetterLife is engaged in the development and commercialization of therapeutic pharmaceuticals as well as drug delivery platform technologies.

Through its wholly owned subsidiary, BLife Therapeutics Inc., BetterLife is refining and developing drug candidates from a broad set of complementary Interferon-based technologies which have the potential to engage the immune system to fight virus infections, such as the coronavirus disease (COVID-19) and human papillomavirus (HPV), and/or to directly inhibit tumours to treat specific types of cancer.

Contact the author at [email protected]

Quick facts: BetterLife Pharma Inc

Price: 1.8695 USD

OTCQB:BETRF
Market: OTCQB
Market Cap: $32.18 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of BetterLife Pharma Inc named herein, including the promotion by the Company of BetterLife Pharma Inc in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

BetterLife surges on UK biotech trial results of interferon inhalation...

BetterLife Pharma Inc (OTCQB:BETRF) (CSE:BETR) CEO Ahmad Doroudian tells Proactive its encouraged by positive results from a clinical trial by a UK biotech, which suggested that an interferon inhalation treatment for coronavirus reduces the need for intensive care. Doroudian says data from...

2 weeks, 6 days ago

2 min read